Molecular serotyping of clinical strains of Haemophilus (Glaesserella) parasuis brings new insights regarding Glässer's disease outbreaks in Brazil
- PMID: 31198621
- PMCID: PMC6535215
- DOI: 10.7717/peerj.6817
Molecular serotyping of clinical strains of Haemophilus (Glaesserella) parasuis brings new insights regarding Glässer's disease outbreaks in Brazil
Abstract
Glässer's disease (GD) is an important infectious disease of swine caused by Haemophilus (Glaesserella) parasuis. Vaccination with inactivated whole cell vaccines is the major approach for prevention of H. parasuis infection worldwide, but the immunity induced is predominantly against the specific polysaccharide capsule. As a consequence, the available vaccines may not induce adequate protection against the field strains, when the capsules present in the vaccine strains are different from those in strains isolated from the farms. Therefore, it is crucial to map H. parasuis serovars associated with regional outbreaks so that appropriate bacterin vaccines can be developed and distributed for prevention of infection. In this study, 459 H. parasuis field strains isolated from different Glässer's disease outbreaks that occurred in 10 different Brazilian States were analyzed for serotype using PCR-based approaches. Surprisingly, non-typeable (NT) strains were the second most prevalent group of field strains and along with serovars 4, 5 and 1 comprised more than 70% of the isolates. A PCR-based approach designed to amplify the entire polysaccharide capsule locus revealed 9 different band patterns in the NT strains, and 75% of the NT strains belonged to three clusters, suggesting that a number of new serovars are responsible for a substantial proportion of disease. These results indicate that commercially available vaccines in Brazil do not cover the most prevalent H. parasuis serovars associated with GD.
Keywords: Brazil; Disease mapping; Haemophilus parasuis; Serovars; Typification; Vaccines.
Conflict of interest statement
Dr. Anthony B. Schryvers is a stakeholder in Engineered Antigens Inc. that holds IP related to vaccines against human and veterinary pathogens, including H. parasuis, but this had no influence on this study. None of the authors of this paper has a financial or personal relationship with private organizations that could inappropriately influence or bias the content of the paper.
Figures
References
-
- Barasuol BM, Guizzo JA, Fegan JE, Martinez-Martinez S, Rodriguez-Ferri EF, Gutierrez-Martin CB, Kreutz LC, Schryvers AB, Frandoloso R. New insights about functional and cross-reactive properties of antibodies generated against recombinant TbpBs of Haemophilus parasuis. Scientific Reports. 2017;7:10377. doi: 10.1038/s41598-017-10627-0. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
